(Reuters) – China’s Sinovac Biotech on Friday said late-stage trial data of its COVID-19 vaccine from Brazil and Turkey showed the inoculation prevented hospitalization and death in COVID-19 patients, but had a much lower efficacy overall.
The 12,396-person trial found the CoronaVac vaccine was 100% effective for hospitalized, severe and fatal cases, 83.7% effective at stopping cases that require medical treatment and 50.65% for all cases, according to a statement.
(Reporting by Vishwadha Chander, editing by Peter Henderson and Sonya Hepinstall)
